Elevance Health Q2 EPS Forecast Lifted by Zacks Research

Elevance Health, Inc. (NYSE:ELV) – Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for Elevance Health in a research report issued on Wednesday, December 18th. Zacks Research analyst K. Dey now forecasts that the company will post earnings per share of $10.35 for the quarter, up from their previous forecast of $10.22. The consensus estimate for Elevance Health’s current full-year earnings is $32.96 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $4.68 EPS, Q2 2026 earnings at $11.90 EPS, Q3 2026 earnings at $10.65 EPS and FY2026 earnings at $40.48 EPS.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.66 by ($1.29). Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The firm had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. During the same quarter last year, the business posted $8.99 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year.

Other analysts also recently issued reports about the stock. Stephens reiterated an “underperform” rating on shares of Elevance Health in a report on Friday, October 18th. Mizuho dropped their price target on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Cantor Fitzgerald reduced their price objective on Elevance Health from $600.00 to $485.00 and set an “overweight” rating for the company in a research note on Friday, October 18th. UBS Group cut their target price on Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a research report on Friday, October 18th. Finally, Argus lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $539.20.

Elevance Health Price Performance

Shares of NYSE ELV opened at $372.94 on Monday. Elevance Health has a twelve month low of $362.21 and a twelve month high of $567.26. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average of $406.93 and a two-hundred day moving average of $487.13. The company has a market capitalization of $86.49 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 1.15 and a beta of 0.83.

Institutional Trading of Elevance Health

Large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Elevance Health by 1.2% in the 3rd quarter. State Street Corp now owns 10,687,998 shares of the company’s stock valued at $5,557,759,000 after purchasing an additional 129,709 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Elevance Health by 1.8% in the third quarter. Geode Capital Management LLC now owns 4,848,020 shares of the company’s stock worth $2,511,814,000 after buying an additional 85,770 shares during the last quarter. Sanders Capital LLC boosted its stake in shares of Elevance Health by 1.0% during the 3rd quarter. Sanders Capital LLC now owns 4,609,258 shares of the company’s stock worth $2,396,814,000 after acquiring an additional 44,805 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Elevance Health by 6.9% during the 3rd quarter. Wellington Management Group LLP now owns 4,461,585 shares of the company’s stock valued at $2,320,024,000 after acquiring an additional 286,905 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Elevance Health by 5.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,791,793 shares of the company’s stock valued at $2,054,641,000 after acquiring an additional 190,118 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Insider Transactions at Elevance Health

In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $432.14, for a total value of $3,205,182.38. Following the transaction, the executive vice president now owns 8,423 shares in the company, valued at approximately $3,639,915.22. This represents a 46.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.29% of the stock is currently owned by company insiders.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, December 20th. Stockholders of record on Thursday, December 5th were issued a dividend of $1.63 per share. This represents a $6.52 annualized dividend and a dividend yield of 1.75%. The ex-dividend date was Thursday, December 5th. Elevance Health’s dividend payout ratio is currently 23.77%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.